Vanguard Group
IMNM icon

Vanguard Group’s Immunome IMNM Stock Holding History

Vanguard Group’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$130M Buy
6,038,414
+1,144,788
+23% +$20.1M ﹤0.01% 1751
2025
Q3 		$57.3M Buy
4,893,626
+368,674
+8% +$3.67M ﹤0.01% 2089
2025
Q2 		$42.1M Buy
4,524,952
+217,761
+5% +$1.79M ﹤0.01% 2213
2025
Q1 		$29M Buy
4,307,191
+1,303,753
+43% +$12.5M ﹤0.01% 2335
2024
Q4 		$31.9M Sell
3,003,438
-128,130
-4% -$1.55M ﹤0.01% 2357
2024
Q3 		$45.8M Buy
3,131,568
+210,356
+7% +$2.99M ﹤0.01% 2220
2024
Q2 		$35.3M Buy
2,921,212
+901,474
+45% +$14.1M ﹤0.01% 2287
2024
Q1 		$49.8M Buy
2,019,738
+279,712
+16% +$5.68M ﹤0.01% 2167
2023
Q4 		$18.6M Buy
1,740,026
+1,343,697
+339% +$11.2M ﹤0.01% 2628
2023
Q3 		$3.31M Buy
396,329
+22,451
+6% +$165K ﹤0.01% 3416
2023
Q2 		$2.96M Hold
373,878
– – ﹤0.01% 3529
2023
Q1 		$1.87M Hold
373,878
– – ﹤0.01% 3701
2022
Q4 		$826K Buy
373,878
+193
+0.1% +$778 ﹤0.01% 3973
2022
Q3 		$1.66M Buy
373,685
+3,149
+0.8% +$14.8K ﹤0.01% 3819
2022
Q2 		$1.19M Hold
370,536
– – ﹤0.01% 4021
2022
Q1 		$2.1M Sell
370,536
-5,822
-2% -$43.5K ﹤0.01% 3937
2021
Q4 		$4.88M Buy
376,358
+3,878
+1% +$69.2K ﹤0.01% 3623
2021
Q3 		$9.07M Buy
372,480
+70,388
+23% +$1.23M ﹤0.01% 3297
2021
Q2 		$5.23M Buy
302,092
+147,863
+96% +$3.27M ﹤0.01% 3577
2021
Q1 		$5.22M Buy
+154,229
New +$3.83M ﹤0.01% 3510

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group's IMNM Position: Q4 2025 in Review

Vanguard Group increased its Immunome (IMNM) stake by 23% in Q4 2025, buying an estimated $20.1M and bringing the position to 6,038,414 shares worth $130M. The position accounts for ﹤0.01% of the portfolio, ranked #1751.

Vanguard Group first reported a position in IMNM in Q1 2021 and has held it in 20 quarters since. 182 funds tracked by Wall St. Rank hold IMNM as of Q4 2025.

  • Vanguard Group held 6,038,414 shares of Immunome worth $130M as of Q4 2025.
  • Vanguard Group bought 1,144,788 Immunome shares in Q4 2025, an estimated $20.1M.
  • Immunome made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1751 holding.
  • Vanguard Group first reported a position in Immunome in Q1 2021 and has held it in 20 quarters since.
  • 182 funds tracked by Wall St. Rank held Immunome as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.